- Home
- DOCU vs AXSM Comparison
DOCU vs AXSM Comparison
Compare DOCU & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DOCU | AXSM |
|---|---|---|
| Founded | 2003 | 2012 |
| Country | United States | United States |
| Employees | 7044 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2B | 12.0B |
| IPO Year | 2018 | 2015 |
Fundamental Metrics
Financial Performance| Metric | DOCU | AXSM |
|---|---|---|
| Price | $52.60 | $229.43 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 17 | 17 |
| Target Price | $63.33 | ★ $211.12 |
| AVG Volume (30 Days) | ★ 3.8M | 878.2K |
| Earning Date | 06-04-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.56 |
| EPS | ★ 0.40 | N/A |
| Revenue | ★ $3,219,500,000.00 | N/A |
| Revenue This Year | $10.58 | $57.24 |
| Revenue Next Year | $7.33 | $55.88 |
| P/E Ratio | $133.44 | ★ N/A |
| Revenue Growth | ★ 8.16 | N/A |
| 52 Week Low | $40.16 | $96.09 |
| 52 Week High | $86.65 | $260.19 |
Technical Indicators
Market Signals| Indicator | DOCU | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 66.28 | 42.60 |
| Support Level | $44.43 | $217.15 |
| Resistance Level | $57.29 | $236.26 |
| Average True Range (ATR) | 1.97 | 9.67 |
| MACD | 0.86 | -2.07 |
| Stochastic Oscillator | 81.03 | 18.57 |
Price Performance
Historical ComparisonAbout DOCU DocuSign Inc.
Docusign offers Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its initial public offering in 2018.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.